FDA Grants Prodarsan® Orphan Drug Designation

Pharming Group NV announced today that its wholly-owned subsidiary, DNage,has received a notice from the FDA that its product Prodarsan® has been awarded an Orphan Drug designation for the treatment of Cockayne Syndrome. Acting as DNage's US agent, Clinquest filed the application.

For more information:

Pharming - Prodarsan® Granted Orphan Drug Designation From FDA